Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunogen Inc (NQ: IMGN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Immunogen Inc < Previous 1 2 3 4 5 Next > ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results October 29, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results October 14, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 01, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors September 22, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results July 30, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results July 15, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 01, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 01, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference May 20, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status May 19, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results May 10, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results April 26, 2021 From ImmunoGen Inc. Via Business Wire ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting April 10, 2021 From ImmunoGen Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.